Inogen, Inc.

NasdaqGS:INGN Voorraadrapport

Marktkapitalisatie: US$174.6m

Inogen Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Inogen de winst en omzet met respectievelijk 51.4% en 6.3% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 36.6% per jaar.

Belangrijke informatie

51.4%

Groei van de winst

36.64%

Groei van de winst per aandeel

Medical Equipment winstgroei16.1%
Inkomstengroei6.3%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt15 May 2026

Recente toekomstige groei-updates

Recent updates

Narratiefupdate • May 09

INGN: Bullish Initiation And Buyback Program Will Support Future Upside

Analysts have trimmed their price target on Inogen from about $13.00 to roughly $12.67, reflecting updated assumptions around revenue, profit margins and future P/E following fresh bullish initiation research from the Street. Analyst Commentary Analysts are using the fresh bullish initiation as a chance to refresh their models, focus on execution and reassess how much they are willing to pay for Inogen at the current P/E.
Narratiefupdate • Apr 19

INGN: Buybacks And New Leadership Will Support Future Returns

Analysts have adjusted their price target on Inogen to $12.00, reflecting updated views on revenue growth assumptions, profit margin expectations, and the valuation multiple following recently published Street research, including a positive initiation of coverage. Analyst Commentary Recent Street research on Inogen has combined a constructive long term narrative with a more restrained tone on execution risks and how much investors are currently being asked to pay for that story.
Narratiefupdate • Apr 04

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Returns

Analysts have adjusted their price target on Inogen to $12.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, which keep the fair value view broadly in line with prior estimates. What's in the News Inogen appointed Jason Richardson as Chief Financial Officer, effective April 6, 2026, succeeding Michael Bourque, who will remain in an advisory role until June 30, 2026 (Key Developments).
Narratiefupdate • Mar 21

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Earnings Power

Analysts have maintained their price target for Inogen at $12.00, making small adjustments to assumptions around the discount rate, revenue growth, profit margin, and future P/E, which together result in an unchanged fair value view. What's in the News Inogen approved a share repurchase program of up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with an expiry on the earlier of December 31, 2027, or when the full amount is used (Key Developments).
Narratiefupdate • Mar 06

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Undervalued Upside

Analysts maintained their fair value estimate for Inogen at $13.00, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E that refine rather than significantly change their prior view. What's in the News Inogen announced a share repurchase program authorizing the company to buy back up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with the program running until the earlier of December 31, 2027, or when the full amount is used (Key Developments).
Narratiefupdate • Feb 20

INGN: Sleep Therapy Portfolio Expansion Will Support Future Earnings Power

Analysts have adjusted their price target on Inogen to $12.00. The change reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.
Narratiefupdate • Feb 06

INGN: Sleep Therapy Expansion Will Support Future Confidence In Undervalued Shares

Analysts have kept their price target for Inogen steady at US$13.00. This reflects only minor tweaks to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock.
Narratiefupdate • Jan 22

INGN: Sleep Therapy Expansion Will Support Future Earnings Power Ahead

Narrative Update on Inogen Analysts have modestly adjusted their price target on Inogen to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. This has led to a refined valuation that still centers around a fair value of $12.00 per share.
Narratiefupdate • Jan 08

INGN: Stable Guidance And New Respiratory Line Will Support Future Confidence

Analysts have kept their price target for Inogen broadly in line with prior views, with only a small adjustment supported by updated assumptions around discount rate, profit margin and future P/E expectations, rather than any major shift in the outlook. What's in the News Inogen launched Aurora CPAP masks as a new product line within its respiratory care portfolio, targeting patients with obstructive sleep apnea through the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows range (Key Developments).
Narratiefupdate • Dec 16

INGN: Rising Revenue Outlook Will Support Stronger Earnings Power Ahead

Analysts have raised their price target on Inogen by approximately $5 to around $12 per share, reflecting modestly higher expectations for revenue growth, profit margins, and future earnings multiples, despite a slightly higher assumed discount rate. What's in the News Issued new fourth quarter 2025 revenue guidance of $87 million to $90 million, implying roughly 10% year over year growth at the midpoint compared to fourth quarter 2024 (company guidance) Reiterated full year 2025 revenue outlook of $354 million to $357 million, targeting about 6% growth at the midpoint versus 2024 revenue (company guidance) Emphasized that the updated outlook reflects confidence in execution while maintaining a disciplined view of demand and pricing conditions in the portable oxygen concentrator market (company guidance) Valuation Changes The fair value estimate has risen materially, increasing from approximately $7.00 to $12.00 per share.
Narratiefupdate • Dec 02

INGN: Guidance Stability Will Drive Confidence As Margins Poised To Improve

Analysts have maintained their price target for Inogen at $13.00. This reflects minimal changes in financial assumptions and a steady outlook for the company's revenue growth and profitability.
Narratiefupdate • Nov 18

INGN: Profit Margins Will Strengthen As Revenue Guidance Remains Encouraging

Analysts have adjusted Inogen’s price target to $13.00. This is a slight change that reflects expectations of improved profit margins, despite modest revisions in growth rates and valuation metrics.
Seeking Alpha • Nov 11

Slow Progress At Inogen ... But Progress All The Same

Summary Inogen (INGN) continues its turnaround, showing progress in revenue growth and margins, but the pace remains slower and riskier than the market desires. INGN posted positive adjusted EBITDA and raised full-year guidance, despite mixed quarterly results and ongoing volatility in direct-to-consumer and rental segments. The company’s strong market position, new product launches, and partnerships offer long-term growth potential, especially as patients consistently prefer portable solutions. Valuation appears deeply discounted, with net cash and little credit for progress; INGN offers speculative upside for risk-tolerant investors if improvements persist. Read the full article on Seeking Alpha
Narratiefupdate • Nov 03

INGN: Profit Margins Will Strengthen Amid Broader Respiratory Care Market Expansion

Analysts have slightly increased their price target for Inogen to $13.00 per share. This change reflects modest adjustments to profit margin forecasts and discount rates in their updated models.
Narratiefupdate • Oct 20

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Analysts have reaffirmed their price target for Inogen at $13.00, citing stable outlooks with only minor adjustments to key financial metrics. What's in the News Inogen issued new earnings guidance for the third quarter of 2025, projecting revenue between $91 million and $93 million.
Narratiefupdate • Oct 05

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Analysts have raised their price target for Inogen from $11.00 to $13.00, citing updated projections of slightly stronger revenue growth and reduced discount rates as key contributors to the increased valuation. What's in the News Inogen, Inc.
Analyseartikel • Aug 31

There's No Escaping Inogen, Inc.'s (NASDAQ:INGN) Muted Revenues Despite A 29% Share Price Rise

The Inogen, Inc. ( NASDAQ:INGN ) share price has done very well over the last month, posting an excellent gain of 29...
Narratiefupdate • Aug 10

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Despite an upward revision in revenue growth forecasts and a lower future P/E, the analyst consensus price target for Inogen has decreased from $11.67 to $11.00, indicating increased caution around the company’s fair value. What's in the News Inogen expects third quarter 2025 revenue of $91–93 million (~4% YoY growth) and full-year 2025 revenue of $354–357 million (~6% YoY growth).
Analyseartikel • May 10

Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report

A week ago, Inogen, Inc. ( NASDAQ:INGN ) came out with a strong set of quarterly numbers that could potentially lead to...
User avatar
Nieuw narratief • Apr 01

Yuwell Collaboration Will Open Chinese Respiratory Market

Strategic partnerships and product innovation in China and digital health are expected to drive growth and improve earnings potential.
Analyseartikel • Mar 08

Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge

Inogen, Inc. ( NASDAQ:INGN ) shareholders won't be pleased to see that the share price has had a very rough month...
Seeking Alpha • Mar 01

A Volatile Share Price Masks Some Of The Progress At Inogen

Summary Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage. Key recent developments include FDA approval of the Simeox device and a strategic partnership with Yuwell, both offering long-term growth potential but requiring time to ramp. While 2024 progress is promising and the valuation is not at all demanding, significant risks remain, particularly in revenue acceleration and margin leverage, making Inogen a high-risk but intriguing speculative investment. Read the full article on Seeking Alpha
Analyseartikel • Feb 28

Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Shareholders in Inogen, Inc. ( NASDAQ:INGN ) had a terrible week, as shares crashed 23% to US$7.95 in the week since...
Analyseartikel • Jan 22

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%

Inogen, Inc. ( NASDAQ:INGN ) shareholders would be excited to see that the share price has had a great month, posting a...
Seeking Alpha • Sep 24

Inogen: Upside Seems Limited After Big Move Up

Summary Inogen, Inc. manufactures portable oxygen concentrators and related accessories. The shares have doubled over the past year, but the equity is still trading at roughly 75% of annual sales. Despite an earnings beat in Q2, Wall Street analysts are cautious about the stock's current prospects. Inogen boasts a strong balance sheet with over $120 million in cash (which is roughly half the stock's market cap) and no long-term debt. An analysis of Inogen follows in the paragraphs below. Read the full article on Seeking Alpha
Analyseartikel • Jul 16

Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Despite an already strong run, Inogen, Inc. ( NASDAQ:INGN ) shares have been powering on, with a gain of 26% in the...
Seeking Alpha • Jul 01

Inogen: Improving, But Still Struggling For Air

Summary Inogen aims to help millions suffering from COPD with portable oxygen delivery machines, but its financial performance has been inconsistent. Inogen faced execution issues, but recent improvements in operating momentum due to competitor exits and new management team are sparking optimism. Recent revenue growth, cost cuts, and narrowing losses are encouraging, but shares remain highly speculative and further progress is needed for a more positive outlook. Read the full article on Seeking Alpha
Analyseartikel • May 22

Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Inogen, Inc. ( NASDAQ:INGN ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...
Seeking Alpha • Apr 13

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Summary Inogen has continued to struggle, with growth in the rental business overshadowed by declines in direct-to-consumer sales, volatility in business-to-business sales, and pricing pressures. Inogen has the opportunity to leverage the exit of a major competitor, Philips, from the portable oxygen concentrator (POC) market. The new management team aims to position Inogen as the premium POC provider and partner with home medical equipment companies, while also focusing on the Physio-Assist opportunity. Inogen shares trade at a steep discount, but the Street typically wants nothing to do with low-growth small-cap med-tech, so management must present a credible plan for meaningful sustained growth. Read the full article on Seeking Alpha
Analyseartikel • Mar 01

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

There's been a major selloff in Inogen, Inc. ( NASDAQ:INGN ) shares in the week since it released its annual report...
Analyseartikel • Feb 01

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Despite an already strong run, Inogen, Inc. ( NASDAQ:INGN ) shares have been powering on, with a gain of 25% in the...

Winst- en omzetgroeiprognoses

NasdaqGS:INGN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2028417-100192
12/31/2027397-131183
12/31/2026369-22-593
3/31/2026351-25-10-1N/A
12/31/2025349-23-22-11N/A
9/30/2025347-25-24-13N/A
6/30/2025343-26-22-8N/A
3/31/2025340-27-21-6N/A
12/31/2024336-36-116N/A
9/30/2024332-53-146N/A
6/30/2024327-92-201N/A
3/31/2024322-97-26-2N/A
12/31/2023316-102-30-3N/A
9/30/2023328-133-43-16N/A
6/30/2023349-96-55-27N/A
3/31/2023369-90-50-26N/A
12/31/2022377-84-59-38N/A
9/30/2022366-50-36-16N/A
6/30/2022353-28-31-9N/A
3/31/2022351-20-203N/A
12/31/2021358-6024N/A
9/30/202135611933N/A
6/30/2021337-22043N/A
3/31/2021307-51939N/A
12/31/2020308-61937N/A
9/30/2020313-21630N/A
6/30/202033162938N/A
3/31/2020360143643N/A
12/31/201936221N/A41N/A
9/30/201937032N/A44N/A
6/30/201937342N/A43N/A
3/31/201936946N/A46N/A
12/31/201835852N/A60N/A
9/30/201833541N/A61N/A
6/30/201830932N/A64N/A
3/31/201827626N/A60N/A
12/31/201724921N/A60N/A
9/30/201723727N/A53N/A
6/30/201722225N/A44N/A
3/31/201721224N/A39N/A
12/31/201620321N/A31N/A
9/30/201619219N/A38N/A
6/30/201617917N/A41N/A
3/31/201616813N/A37N/A
12/31/201515912N/A38N/A
9/30/20151489N/A30N/A
6/30/20151369N/A21N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat INGN de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat INGN de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat INGN de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van INGN ( 6.3% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.6% per jaar).

Hoge groei-inkomsten: De omzet van INGN ( 6.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van INGN naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/20 19:02
Aandelenkoers aan het einde van de dag2026/05/20 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Inogen, Inc. wordt gevolgd door 9 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Anderson SchockB. Riley Securities, Inc.
Ilya ZubkovFreedom Broker
Matthew MishanKeyBanc Capital Markets Inc.